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Abstract
Objective—To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like 
receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic 
subtypes, and overall survival.
Patients and Methods—We conducted centralized immunohistochemical staining, semi-
quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor 
Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 
2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 
person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and 
staining intensity was classified using a 2-tiered system for each marker (weak vs strong).
Results—Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian 
cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In 
HGSOC, strong MyD88 expression was modestly associated with shortened overall survival 
(hazard ratio [HR], 1.13; 95% CI, 1.01–1.26; P=.04) but was also associated with advanced stage 
(P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian 
cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable 
survival (HR [95% CI], 0.49 [0.29–0.84] and 0.44 [0.21–0.89], respectively; P=.009 and P=.02, 
respectively).
Conclusion—Results are consistent with an association between strong MyD88 staining and 
advanced stage and poorer survival in HGSOC and demonstrate correlation between strong 
MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological 
differences between the 2 serous histotypes.
Epithelial ovarian cancer (EOC) remains the fifth leading cause of cancer death among 
women in United States, resulting in more than 14,000 estimated deaths in 2017.1 Less than 
40% of patients with EOC are cured, because more than 70% of patients are diagnosed with 
advanced disease (stage III or IV).2 The frustrating truth is that since platinum-based 
treatment was introduced more than 30 years ago, the overall survival rate of women with 
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EOC has changed little3; most patients will relapse and die from their disease despite 
response to first-line surgery and chemotherapy.4 Thus, novel therapeutic approaches for 
EOC are needed.5
The innate immune system recognizes the presence of bacterial pathogens through the 
expression of a family of membrane receptors known as Toll-like receptors (TLRs).6 
Although their expression is well established in immune cells, TLRs are also found in a 
myriad of human cancers, including EOC.7 Among all the TLRs, Toll-like receptor 4 
(TLR4) is perhaps the most extensively investigated.8 Cumulating studies have suggested 
that coexpression of TLR4, along with myeloid differentiation primary response gene 88 
(MyD88), a TLR signaling adapter protein, associates with poor prognosis in EOC by 
facilitating proliferation, survival, and chemoresistance of EOC cells through the activation 
of various proinflammatory cytokines and antiapoptotic proteins.9–11 An additional report of 
atractylenolide-I, a novel TLR4-antagonizing agent, has been shown to sensitize EOC cells 
to paclitaxel by blocking the MyD88/TLR4 pathway.12
We previously analyzed immunohistochemical staining of MyD88 and TLR4 in a collection 
of approximately 450 EOC cases seen at Mayo Clinic; we found that the expression of both 
MyD88 and TLR4 was associated with poorer overall survival at P< .05.13 Although 
adjustment of clinical covariates such as age, stage, histology, grade, and surgical debulking 
status attenuated these results, MyD88- and TLR4-associated risk estimates remained 
suggestive and indicated the need for larger analyses.13
Therefore, we here report analysis of an independent EOC study population of more than 10 
times the previous sample size, allowing for a more detailed assessment of prognosis by 
histotype with consideration of combined expression and clinical subsets.
PATIENTS AND METHODS
Eligible cases with primary diagnosis of epithelial ovarian, peritoneal, or fallopian tube 
cancer were diagnosed between January 1, 1978, and December 31, 2014, and enrolled into 
21 collaborative studies participating in the Ovarian Tumor Tissue Analysis consortium.
14–17
 Mayo Clinic cases in the original report were not included.13 Histopathological 
classification for each case was provided by each contributing study, which was 
supplemented by additional pathologic review guided by WT1 and p53 IHC staining for 
most studies as described previously.14 From among 7377 cases arrayed on tissue 
microarrays (TMAs), we excluded those found to be duplicated across studies (n=4), 
missing vital status at last follow-up (n=288), missing time to last follow-up (n=17), missing 
age at diagnosis (n=11), found to be nonepithelial (n=63), missing tumor behavior (n=2), or 
unable to be scored for both markers because of inadequate amount of arrayed tumor tissue 
(n=1729) (Supplemental Figure, available online at http://www.mayoclinicproceedings.org). 
Thus, up to 5263 cases were used for analysis, including 4694 with tumors of the 5 major 
invasive histotypes (high-grade serous ovarian carcinoma [HGSOC]; endometrioid ovarian 
carcinoma [ENOC]; clear cell ovarian carcinoma [CCOC]; mucinous ovarian carcinoma 
[MOC]; and low-grade serous ovarian carcinoma [LGSOC]). As described below, additional 
cases were excluded for one marker or the other. Supplemental Table 1 (available online at 
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http://www.mayoclinicproceedings.org) presents characteristics of participating studies, 
including sample size, location, and data collection methods, and Supplemental Table 2 
(available online at http://www.mayoclinicproceedings.org) presents clinical characteristics 
of analyzed cases.
Immunohistochemistry
Sections of TMAs were provided for centralized immunostaining at the Mayo Clinic, 
Rochester, Minnesota. For MyD88, the primary antibody was the rabbit polyclonal antibody 
NBP1-19785 (Novus Biologicals)18 and the detection system was Polymer Refine Detection 
System (Leica). This system included the hydrogen peroxidase block, postprimary and 
polymer reagent 3,3′-diaminobenzidine (DAB), and hematoxylin. Immunostaining 
visualization was achieved by incubating slides for 10 minutes in DAB and DAB buffer 
(1:19 mixture) from the Bond Polymer Refine Detection System. To this point, slides were 
rinsed between steps with 1′ Bond Wash Buffer (Leica). Before and after DAB incubation, 
slides were rinsed in distilled water. For TLR4, the monoclonal antibody 3B6 (Novus 
Biologicals) was used as the primary detection antibody.19 The detection system was the 
Envision Flex System (Dako); the reagents were the Flex Peroxidase-Blocking for 5 
minutes, Flex/HRP for 20 minutes, and Flex DAB+ Chromogen/Substrate Buffer (1 drop of 
DAB per 1 mL of substrate buffer) for 5 minutes. Slides were counterstained for 5 minutes 
using Schmidt hematoxylin and molecular biology grade water (1:1 mixture), followed by 
several rinses in 1′ Bond wash buffer and distilled water; this is not the hematoxylin 
provided with the Refine kit. Once the immunochemistry processes were completed, slides 
were removed from the stainer and rinsed in tap water for 5 minutes. Slides were dehydrated 
in increasing concentrations of ethyl alcohol and cleared in 3 changes of xylene before 
permanent cover-slipping in xylene-based medium.
Scoring
Figure 1 shows representative stains with each score for MyD88 and TLR4. For MyD88, 
multiple cores from a subset of 312 cases were evaluated blindly by 2 independent 
pathologists (M.K. and P.R.) using a 4-tiered system (negative, weak, moderate, and strong), 
and a weighted kappa statistic was estimated. Then, differences in interpretation were 
discussed at a multiheaded microscope. Assessments of concordance in scores across these 
MyD88 cores indicated only modest levels of agreement (weighted κ, 0.55; 95% CI, 0.48–
0.62); dichotomization of MyD88 expression into negative/weak and moderate/strong 
substantially increased agreement (κ, 0.81; 95% CI, 0.72–0.90). Because of this, all 
subsequent analyses of MyD88 and TLR4 expression used a dichotomous classification, 
henceforth referred to as weak (negative or weak expression) or strong (moderate or strong 
expression).
The cohort was subsequently split, with 51% of cases scored for MyD88 by M.K. and 49% 
by P.R. The TLR4 was evaluated by a single pathologist (M.K.). For cases with more than 1 
scored core, the highest score was used in analysis. Because TMA cores with less than 25% 
epithelial tumor component were considered uninterpretable, a total of 137 cases were not 
scored for MyD88 (therefore, 5126 analyzed) and 676 cases were not scored for TLR4 
(therefore, 4587 analyzed) (Supplemental Figure).
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Analysis
Three sets of potential prognostic factors were evaluated: tumor expression of MyD88, of 
TLR4, and combinations of these 2. All statistical tests were 2-sided and uncorrected for 
multiple testing; all analyses were carried out using the SAS (SAS System, Inc) and R 
software (R Foundation for Statistical Computing) systems. Details on statistical analysis are 
provided in Supplemental Methods (available online at http://
www.mayoclinicproceedings.org).
RESULTS
Clinical Characteristics of Study Cohort
The mean age at diagnosis for study participants was 58.0 years (Supplemental Table 2). 
Most of the cancers were advanced stage and high grade, and more than half of the patients 
were deceased as of last follow-up. Among the 5 main invasive EOC histotypes (N=4694), 
HGSOC was the most common (N=2865, 61%), followed by ENOC (N=670, 14%), CCOC 
(N=616, 13%), MOC (N=355, 7%), and LGSOC (N=188, 4%). Ten-year overall Kaplan-
Meier survival estimates were 19% for HGSOC, 66% for ENOC, 50% for CCOC, 53% for 
MOC, and 30% for LGSOC.
Intracellular Distribution of Staining
The MyD88 staining distribution was mostly cytoplasmic with some membranous staining, 
consistent with the primarily cytoplasmic localization of the MyD88 adapter protein. Toll-
like receptor 4 staining was distributed to both the cytoplasm and the plasma membrane. 
Toll-like receptor 4 is typically expressed both on the plasma membrane and in endosomes 
of myeloid leukocytes; localization of TLR4 expression on tumor cells has not previously 
been reported.
Distribution of Expression by Histotype
Distributions of MyD88 and TLR4 expression among the 5 most common invasive 
histotypes are presented in Table 1. In general, strong expression was more common than 
weak expression, with a notable exception: a minority of CCOCs (40%) showed strong 
TLR4 expression. Expression distributions for each marker were similar across HGSOCs, 
ENOCs, MOCs, and LGSOCs (68%–74% strong for MyD88; 71%–74% strong for TLR4). 
However, the expression in CCOCs was lower (only 59% strong for MyD88; only 40% 
strong for TLR4) compared with that of these histotypes combined (MyD88 P<.001; TLR, 
P<.001). Distributions among additional histopathological groups are provided in 
Supplemental Table 3 (available online at http://www.mayoclinicproceedings.org). Both 
MyD88 and TLR4 tended to be coexpressed, such that 67% of subjects either had low 
expression of both or high expression of both (χ2 tests for independence P<.001, both 
overall and subset to the 5 most common invasive histotypes).
Clinical Correlates Among Women With HGSOC
Among women with HGSOC, associations of expression with clinical features are presented 
in Supplemental Table 4 (available online at http://www.mayoclinicproceedings.org). 
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Expression was similar regardless of age at diagnosis (P=.65 for MyD88 and P=.12 for 
TLR4). High-grade serous ovarian carcinomas with strong MyD88 expression were more 
likely to be advanced stage than those with weak MyD88 expression (82% vs 75%, P<.001). 
The expression of TLR4 did not differ by tumor stage (P=.75). Expression did not differ by 
extent of residual disease or known breast cancer susceptibility gene 1 (BRCA1) or breast 
cancer susceptibility gene 2 (BRCA2) pathogenic mutation.
Associations of Expression With Overall Survival by Histotype
Women with HGSOC and strong MyD88 expression had slightly poorer survival than did 
those with weak expression (unadjusted log-rank test P<.001; Figure 2). Results attenuated 
somewhat in age- and stage-adjusted Cox regression analyses but remained statistically 
significant (hazard ratio [HR], 1.13; 95% CI, 1.01–1.26; P=.04; Table 1). We found no 
evidence of a survival association with MyD88 expression for women with ENOC, CCOC, 
and MOC. Women with LGSOC and strong MyD88 expression had marginally better 
survival outcomes than did those with weak MyD88 expression (unadjusted log-rank test P=.
14, Figure 2). This association strengthened after adjustment for study, age, and stage (Cox 
regression HR, 0.49; 95% CI, 0.29–0.84; P=.009; Table 1). Sensitivity analyses adjusting 
only for age and tumor stage demonstrated a similar protective effect of high MyD88 levels 
on survival (HR, 0.61; 95% CI, 0.39–0.97; P=.04).
For TLR4, even with nearly 12,000 years of follow-up for 2522 HGSOC cases (1737 
deaths), we found no discernable evidence that survival differed by TLR4 expression. 
Kaplan-Meier curves overlapped considerably (Figure 3), and Cox regression analyses 
adjusting for age, stage, and study site were not statistically significant (HR, 1.06; 95% CI, 
0.94–1.18; Table 1). There was some evidence for nonproportional hazards over time for 
women with HGSOC (P=.01). This can be seen in Figure 3, where the Kaplan-Meier curves 
cross in such a way that strong expression has a slight protective effect within the first 5 
years of follow-up, then a slightly increased prognostic effect in years 5 through 10. 
However, in no instance is the difference between the 2 curves clinically meaningful. 
Moreover, time-stratified Cox regression analysis found no evidence of association with 
survival in either the first 5 years (P=.37) or the last 5 years of follow-up (P=.80).
We also did not observe any significant associations between TLR4 expression and overall 
survival for women with ENOC (Cox regression P=.99) or CCOC (P=.76) (Table 1). In 
univariate analyses, MOC tumors with strong TLR4 expression tended to fare better than 
those with weak expression (log-rank test P<.001; Figure 3). This association reversed 
direction in Cox regression analyses adjusting for study, age, and stage, such that MOC 
tumors with strong TLR4 expression fared more poorly than did those with weak expression, 
although the results failed to reach statistical significance (HR, 1.54; 95% CI, 0.91–2.60; P=.
11; Table 1). Sensitivity analyses revealed that adjustment for study site had the most impact 
on this change in direction of association: analyses adjusting for age and tumor stage only 
were essentially null (HR, 1.01; 95% CI, 0.67–1.54; P=.95). Kaplan-Meier curves displayed 
some evidence of a survival advantage for patients with LGSOC with strong TLR4 
expression compared to those with weak expression. This effect was even more pronounced 
and reached statistical significance in adjusted Cox regression analyses (HR for strong 
Block et al. Page 5
Mayo Clin Proc. Author manuscript; available in PMC 2018 March 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expression compared with weak, 0.44; 95% CI, 0.21–0.89; P=.02; Table 1). As with MOC, 
analyses adjusting only for age and tumor stage were less striking (HR, 0.72; 95% CI, 0.43–
1.20; P=.21).
Associations of Combined Expression With Overall Survival by Histotype
Because MyD88 and TLR4 coexpression has been shown to affect in vitro function,9–11 we 
examined associations between survival and combination of expression (Figure 4 and Table 
2). For women with HGSOC, those with strong MyD88 expression had poorer survival than 
those with weak MyD88 expression, regardless of TLR4 expression. As with the 
uncombined analyses in Table 1, we found no discernable patterns with survival and 
combinations of MyD88 and TLR4 expression in women with ENOC or CCOC (Cox 
regression P>.50 for each). Consistent with the associations observed in uncombined 
analyses, we saw little or no separation of survival curves for MyD88 expression, regardless 
of TLR4 expression, and we saw some association between high TLR4 expression and 
survival regardless of MyD88 expression for MOC tumors (P=.01; Figure 4). Again, 
consistent with uncombined analyses, associations attenuated to nonsignificance after 
multivariate adjustment (Cox regression P=.52, Table 2). Compared with LGSOC tumors 
with weak expression of both markers, those with weak MyD88 and strong TLR4 expression 
(HR, 0.87; 95% CI, 0.28–2.71) and those with strong MyD88 and weak TLR4 expression 
(HR, 0.78; 95% CI, 0.28–2.21) had slightly longer survival. The LGSOC tumors with strong 
expression for both MyD88 and TLR4 had the longest survival times of the 4 expression 
groups (HR, 0.33; 95% CI, 0.13–0.85). We found no statistically significant survival 
interactions between MyD88 expression and TLR4 expression, either overall or by any of 
the histotypes in Table 1, indicating that effects of MyD88 expression on survival are not 
modified by expression of TLR4 and vice versa (interaction P>.05 for each).
Associations of Expression With Overall Survival in HGSOC Subsets
We evaluated the association between MyD88 and TLR4 expression and overall survival of 
HGSOCs by the extent of disease following surgery, BRCA1 or BRCA2 pathogenic 
mutation, and treatment (Table 3). For MyD88, the modest prognostic association remained; 
HRs were elevated in each group. For TLR4, there was a suggestion of effect modification 
by extent of residual disease (macroscopic disease: HR, 1.17; 95% CI, 0.98–1.39; P=.084; 
no macroscopic disease: HR, 0.76; 95% CI, 0.59–0.97; P=.03), but tests for interaction failed 
to reach statistical significance (P=.13). We also observed a potential prognostic association 
of TLR4 in BRCA1 mutation carriers (HR, 2.69; 95% CI, 1.25–5.81; P=.01) and a potential 
protective effect in BRCA2 carriers (HR, 0.26; 95% CI, 0.08–0.84; P=.02), but tests for 
interaction again failed to reach statistical significance (P=.08), perhaps due in part to small 
cell sizes within the mutation-positive groups. Combining MyD88 and TLR4 expression did 
not reveal additional patterns or interactions between the 2 expression values (Supplemental 
Table 5, available online at http://www.mayoclinicproceedings.org).
Additional Analyses
Because some previous ovarian cancer studies have combined LGSOC and HGSOC, we also 
analyzed invasive serous cases as a group, including those with missing grade. As expected, 
we found that combining the 2 groups together nullified the modestly higher expression-
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related associations observed in HGSOCs and the strikingly lower risks observed in 
LGSOCs (P=.21 for MyD88 and P=.49 for TLR4; see Supplemental Table 6, available 
online at http://www.mayoclinicproceedings.org). Combining LGSOCs with 127 serous 
borderline tumors (a potential precursor lesion) resulted in a similar protective association 
with strong MyD88 and TLR4 expression levels that we had observed in LGSOC-only 
analyses. No discernable patterns were observed between expression (including combined) 
and survival (including interactions) in other histological groups (Supplemental Tables 6 and 
7, available online at http://www.mayoclinicproceedings.org), although results for many of 
these should be interpreted with caution because of low sample sizes.
Last, among the 5 major histotypes, time to disease progression was known for 
approximately half the cases. Progression-free survival results were similar to overall 
survival results (Supplemental Tables 8 and 9, available online at http://
www.mayoclinicproceedings.org). Note that the number of tests conducted is not small, no 
correction for multiple testing was done, and sample sizes are quite reduced in subset 
analyses.
DISCUSSION
Toll-like receptors, including TLR4, were originally described as myeloid leukocyte 
receptors for pathogen-associated molecular patterns, conserved structures present on 
subsets of pathogens but absent on normal host cells.20 More recently, multiple 
endogenously expressed molecules (damage-associated molecular patterns) have been 
shown to stimulate myeloid cells via a TLR-dependent mechanism.21 Specifically, TLR4 has 
been demonstrated to be stimulated by hsp60, hsp70, hsp90B1, heparan sulfate, fibrinogen, 
HMGB1, BD-2, and additional endogenous molecules.21 Many of these damage-associated 
molecular patterns are present in the EOC microenvironment13 and could therefore drive 
intracellular signaling through MyD88 and TLR4 in EOC cells expressing these proteins. 
The ligation of TLR4 triggers recruitment of the adapter protein MyD88 to the receptor 
complex. Upon recruitment, MyD88, in turn, recruits the kinases IL-1 receptor-associated 
kinase 1 and receptor-associated kinase 4. Once active, receptor-associated kinase 1 and 
receptor-associated kinase 4 recruit TNF receptor–associated factor 6, which activates IκB 
kinase. The activation of IκB kinase causes degradation of inhibitor of kappa B, promoting 
nuclear translocation and signaling by nuclear factor kappa B.22 The signaling of nuclear 
factor kappa B generates proliferative and antiapoptotic signals in EOC cells.23,24
We and others have previously suggested that MyD88 expression is associated with poorer 
survival in EOC.13,25 This association was confirmed in the present study only for patients 
with HGSOC, albeit with a relatively modest magnitude of effect after adjustment for age at 
diagnosis, disease stage, and study site. A likely explanation for the somewhat attenuated 
effect in the covariate-adjusted analysis is that MyD88 also is associated with advanced 
stage HGSOC. Thus, at least part of the impact of MyD88 on survival may be explained by 
its association with advanced disease. In sharp contrast with HGSOC, improved survival in 
LGSOC was associated with higher MyD88 expression. Furthermore, TLR4 expression also 
correlated positively with survival in LGSOC. Although the mechanism behind these 
divergent effects is not clear, the dichotomy of MyD88 and TLR4 associations between 
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HGSOC and LGSOC adds further evidence that these 2 histotypes are biologically distinct. 
Understudied LGSOCs need additional investigation. Another of the understudied 
histotypes, MOC, showed a nonsignificant association between TLR4 expression and 
prognosis, although this result was more pronounced before accounting for the effects of 
study site; consideration of similarities with gastrointestinal tumors may help to unravel its 
biology.26
Although this study is the largest to examine the adaptor protein MyD88 and the pathogen-
associated molecular pattern receptor TLR4, several significant limitations were 
unavoidable. First, the level of agreement between the 2 scorers for 4-scale MyD88 
expression was modest, leading to the final analysis being performed on dichotomized data. 
A likely reason for the lower level of agreement with a 4-variable categorization is that the 
overall staining intensity of MyD88 was relatively modest. This change to a 2-variable 
categorization improved interscorer agreement but might limit the sensitivity of the analysis 
to detect subtle effects of MyD88 on survival. However, because this limitation would 
reduce sensitivity for detecting association between MyD88 staining intensity and survival, 
it would not be expected to contribute to false-discovery rate. We suggest that future studies 
consider other ways to measure MyD88 and TLR4 expression, perhaps by calculating the 
actual percent of cells positively stained.
CONCLUSION
The current study supports an association between increased MyD88 expression and poor 
survival in HGSOC and demonstrates that increased MyD88 expression is also associated 
with advanced stage HGSOC. In addition, the study suggests that both MyD88 expression 
and TLR4 expression are associated with favorable survival in LGSOC.
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FIGURE 1. 
Representative immunohistochemical stains for MyD88 and TLR4 expression. A, High-
grade serous carcinoma with weak MyD88 staining. B, High-grade serous carcinoma with 
weak TLR4 staining. C, High-grade serous carcinoma with strong MyD88 staining. D, 
High-grade serous carcinoma with strong TLR4 staining. MyD88 = myeloid differentiation 
primary response gene 88; TLR4 = Toll-like receptor 4.
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FIGURE 2. 
Kaplan-Meier overall survival plots by MyD88 expression for the 5 most common invasive 
ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2776); B, endometrioid 
ovarian cancer (N=660); C, clear cell ovarian cancer (N=608); D, mucinous ovarian cancer 
(N=345); and E, low-grade serous ovarian cancer (N=182). MyD88 = myeloid 
differentiation primary response gene 88.
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FIGURE 3. 
Kaplan-Meier overall survival plots by TLR4 expression for the 5 most common invasive 
ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2522); B, endometrioid 
ovarian cancer (N=612); C, clear cell ovarian cancer (N=561); D, mucinous ovarian cancer 
(N=303); and E, low-grade serous ovarian cancer (N=145). TLR4 = Toll-like receptor 4.
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FIGURE 4. 
Kaplan-Meier overall survival plots by MyD88 and TLR4 expression for the 5 most 
common invasive ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2433); 
B, endometrioid ovarian cancer (N=602); C, clear cell ovarian cancer (N=293); D, mucinous 
ovarian cancer (N=553); and E, low-grade serous ovarian cancer (N=139). MyD88 = 
myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.
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